Sign Up to Receive Your Personalised Learning Resources
Start Learning
Sutimlimab potently inhibits the classical complement pathway, with efficacy against cold agglutinin disease
Paroxysmal nocturnal hemoglobinuria: from biology to bedside
Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma
Tackling unmet needs in chronic myeloid leukaemia: What’s next in the treatment algorithm?
Facing clinical challenges associated with paroxysmal nocturnal haemoglobinuria
The role of transplant and biologics in mantle cell lymphoma: Updates from ASH 2022, Swaminathan Iyer
Reducing the burden of managing multiple myeloma with oral therapies
Getting personal: Individualizing therapy for cold agglutinin disease
Drug development in acute myeloid leukaemia picks up pace
Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
Advancing the management of MDS and AML: Novel immune-based approaches
View
Stephen Ansell: Hodgkin lymphoma – what are the treatment challenges?
View
CAR-T cell therapy and bispecifics in the treatment of lymphoma: Updates from ASH 2022, Swaminathan Iyer
View
What’s on the horizon for higher-risk MDS? An update on emerging novel agents
View
Exploring the latest data on new and emerging treatments for the improvement of outcomes in higher-risk MDS and newly diagnosed AML
View
What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
View
William Townsend: Follicular lymphoma – final analysis of the GALLIUM study of obinutuzumab plus chemotherapy
View
Drug development in acute myeloid leukaemia picks up pace
View
Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma
View
Barbara Eichhorst: Venetoclax and obinutuzumab in patients with CLL
View